Nano-enabled biomarker discovery and detection

Biomarkers in Medicine

Volumn 5, Issue 3, 2011, Pages 387-396

  Rakowska, Paulina D ^a   Ryadnov, Maxim G ^a,b  

^a NATIONAL PHYSICAL LABORATORY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

amyloid b; biomarker; biomarker harvesting; cancer; integrins; nanoparticles; neurodegenerative disease; proteomics

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; NANOMATERIAL;

CANCER DIAGNOSIS; DEGENERATIVE DISEASE; FUNCTIONAL PROTEOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NANOANALYSIS; NANOSENSOR; NANOTECHNOLOGY; PHYSICAL CHEMISTRY; PROTEIN ANALYSIS; REVIEW; STRUCTURE ANALYSIS;

BIOLOGICAL MARKERS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEOMICS;

EID: 79958790279     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.26     Document Type: Review

References (88)

1. Atkinson AJ, Colburn WA, DeGruttola VG et al.: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001). (Pubitemid 32225406)
2. Westermeier R, Marouga R: Protein detection methods in proteomics research. Biosci. Rep. 25(1), 19-32 (2005). (Pubitemid 41437707)
3. Hamacher M, Eisenacher M, Stephan C et al.: Instruments and methods in proteomics. In:Data Mining in Proteomics . (Eds).Humana Press, NJ, USA, 3-26 (2011).
4. Musselman I, Speicher DW: Human serum and plasma proteomics. Curr. Protoc. Protein Sci. 24, 241 (2005).
5. Posch A, Martosella J, Zolotarjova N: Multi-component immunoaffinity subtraction and reversed-phase chromatography of human serum. In: 2D PAGE: Sample Preparation and Fractionation. Humana Press, NJ, USA, 27-39 (2008).
6. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW: Investigating diversity in human plasma proteins. Proc. Natl Acad. Sci. USA 102(31), 10852-10857 (2005). (Pubitemid 41105956)
7. Olver CS, Webb TL, Long LJ, Scherman H, Prenni JE: Comparison of methods for depletion of albumin and IgG from equine serum. Vet. Clin. Pathol. 39(3), 337-345 (2010).
8. Bellei E, Bergamini S, Monari E et al.: High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids 40(1), 145-156 (2010).
9. Fitzgerald A, Walsh BJ: New method for prefractionation of plasma for proteomic analysis. Electrophoresis 31(21), 3580-3585 (2010).
10. Albuquerque CP, Smolka MB, Payne SH, Bafna V, Eng J, Zhou H: A multidimensional chromatography technology for in-depth phosphoproteome analysis. Mol. Cell Proteomics 7(7), 1389-1396 (2008). (Pubitemid 352038280)
11. Chu C, Liu R: Application of click chemistry on preparation of separation materials for liquid chromatography. Chem. Soc. Rev. 40(5), 2177-2188 (2011).
12. Bang H, Epps HL, Zhou XK, Mazumdar M, Wu Z, Wu Z: Exploration, visualization, and preprocessing of high-dimensional data. In: Statistical Methods in Molecular Biology. Humana Press, NJ, USA, 267-284 (2010).
13. Wu CH, Chen C, Bandeira N: Protein identification by spectral networks analysis. In: Bioinformatics for Comparative Proteomics. Humana Press, NJ, USA, 151-168 (2011).
14. Domon B, Aebersold R: Options and considerations when selecting a quantitative proteomics strategy. Nat. Biotech. 28(7), 710-721 (2010).
15. Becker CH, Bern M: Recent developments in quantitative proteomics. Mutation Res. DOI: 101016/j.mrgentox.201006.016 (2010) (Epub ahead of print).
16. Askenazi M, Marto JA, Linial M: The complete peptide dictionary - a meta-proteomics resource. Proteomics 10(23), 4306-4310 (2010).
17. Walls D, Loughran ST, Geiser L, Dayon L, Vaezzadeh AR, Hochstrasser DF: Shotgun proteomics: a relative quantitative approach using off-gel electrophoresis and LC-MS/MS. In: Protein Chromatography. Humana Press, NJ, USA, 459-472 (2011).
18. Han X, Aslanian A, Yates JR 3rd: Mass spectrometry for proteomics. Curr. Opin. Chem. Biol. 12(5), 483-490 (2008).
19. Kim J, Kim BC, Lopez-Ferrer D, Petritis K, Smith RD: Nanobiocatalysis for protein digestion in proteomic analysis. Proteomics 10(4), 687-699 (2010).
20. Wehr T: Top-down versus bottom-up approaches in proteomics. LCGC North Am. 24(9), 1004-1010 (2006).
21. Macek B, Waanders LF, Olsen JV, Mann M: Top-down protein sequencing and MS3 on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer. Mol. Cell Proteomics 5(5), 949-958 (2006). (Pubitemid 43792803)
22. McLafferty FW, Breuker K, Jin M et al.: Top-down MS, a powerful complement to the high capabilities of proteolysis proteomics. FEBS J. 274(24), 6256-6268 (2007). (Pubitemid 350215920)
23. Gautier JC, Léonard JF, Courcol M, Gautier JC: Optimization of SELDI for biomarker detection in plasma. In: Drug Safety Evaluation. Humana Press, 351-368 (2011).
24. Liu H, Hou D, Wu D, Yin H, Wu X: Serum pattern profiling for analyzing different types of stress by protein chip technology: a preliminary study. Eur. J. Mass Spectrom. 16(5), 619-623 (2010).
25. Cazares LH, Diaz JI, Drake RR, Semmes OJ: MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers. Methods Mol. Biol. 428, 125-140 (2008).
26. Hall SE: Chemoproteomics-driven drug discovery: addressing high attrition rates. Drug Discov. Today 11(11-12), 495-502 (2006).
27. Tate E: Recent advances in chemical proteomics: exploring the post-translational proteome. J. Chem. Biol. 1(1), 17-26 (2008).
28. Oda Y, Owa T, Sato T et al.: Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 75(9), 2159-2165 (2003). (Pubitemid 36542358)
29. Honda A, Komatsu H, Kato D et al.: Newly developed chemical probes and nano-devices for cellular analysis. Anal. Sci. 24(1), 55-66 (2008).
30. Carlson EE: Natural products as chemical probes. ACS Chem. Biol. 5(7), 639-653 (2010).
31. Cai D, Ren L, Zhao H et al.: A molecular-imprint nanosensor for ultrasensitive detection of proteins. Nat. Nanotechnol. 5, 597-601 (2010).
32. Cui Y, Wei Q, Park H, Lieber CM: Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 293(5533), 1289-1292 (2001). (Pubitemid 32777412)
33. Ndieyira JW, Watari M, Barrera AD et al.: Nanomechanical detection of antibiotic-mucopeptide binding in a model for superbug drug resistance. Nat. Nanotechnol. 3(11), 691-696 (2008).
34. Eustis S, El-Sayed MA: Why gold nanoparticles are more precious than pretty gold: noble metal surface plasmon resonance and its enhancement of the radiative and nonradiative properties of nanocrystals of different shapes. Chem. Soc. Rev. 35, 209-217 (2006). (Pubitemid 43327142)
35. Baptista P, Pereira E, Eaton P et al.: Gold nanoparticles for the development of clinical diagnosis methods. Anal. Bioanal. Chem. 391(3), 943-950 (2008).
36. Yurkov G, Fionov A, Koksharov Y, Koleso V, Gubin S: Electrical and magnetic properties of nanomaterials containing iron or cobalt nanoparticles. Inorg. Mater. 43(8), 834-844 (2007).
37. Andrade ÂL, Souza DM, Pereira MC, Fabris JD, Domingues RZ: Magnetic properties of nanoparticles obtained by different chemical routes. J. Nanosci. Nanotechnol. 9, 2081-2087 (2009).
38. Aubin-Tam M-E, Hamad-Schifferli K: Structure and function of nanoparticle- protein conjugates. Biomed. Mater. 3(3), 034001 (2008).
39. Maus L, Spatz JP, Fiammengo R: Quantification and reactivity of functional groups in the ligand shell of PEGylated gold nanoparticles via a fluorescence-based assay. Langmuir 25(14), 7910-7917 (2009).
40. Porta F, Speranza G, Krpetic Z, Dal Santo V, Francescato P, Scarì G: Gold nanoparticles capped by peptides. Mat. Sci. Eng. B 140(3), 187-194 (2007). (Pubitemid 46962965)
41. Liu Y, Shipton MK, Ryan J, Kaufman ED, Franzen S, Feldheim DL: Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly(ethylene glycol) monolayers. Anal. Chem. 79(6), 2221-2229 (2007). (Pubitemid 46449000)
42. Geho DH, Jones CD, Petricoin EF, Liotta LA: Nanoparticles: potential biomarker harvesters. Curr. Opin. Chem. Biol. 10(1), 56-61 (2006). (Pubitemid 43202288)
43. Cheng MM, Cuda G, Bunimovich YL et al.: Nanotechnologies for biomolecular detection and medical diagnostics. Curr. Opin. Chem. Biol. 10(1), 11-19 (2006). (Pubitemid 43202282)
44. Shrivas K, Wu HF: Modified silver nanoparticle as a hydrophobic affinity probe for analysis of peptides and proteins in biological samples by using liquid-liquid microextraction coupled to AP-MALDI-ion trap and MALDI-TOF mass spectrometry. Anal. Chem. 80(7), 2583-2589 (2008). (Pubitemid 351499842)
45. Stumpo KA, Russell DH: Anion effects on ionization efficiency using gold nanoparticles as matrices for LDI-MS. J. Phys. Chem. C 113(5), 1641-1647 (2009).
46. Sherrod SD, Diaz AJ, Russell WK, Cremer PS, Russell DH: Silver nanoparticles as selective ionization probes for analysis of olefins by mass spectrometry. Anal. Chem. 80(17), 6796-6799 (2008).
47. Lin PC, Tseng MC, Su AK, Chen YJ, Lin CC: Functionalized magnetic nanoparticles for small-molecule isolation, identification, and quantification. Anal. Chem. 79, 3401-3408 (2007).
48. Huang YF, Chang HT: Analysis of adenosine triphosphate and glutathione through gold nanoparticles assisted laser desorption/ionization mass spectrometry. Anal. Chem. 79(13), 4852-4859 (2007).
49. Keighron JD, Keating CD: Enzyme:nanoparticle bioconjugates with two sequential enzymes: stoichiometry and activity of malate dehydrogenase and citrate synthase on au nanoparticles. Langmuir 26(24), 18992-19000 (2010).
50. Maus L, Dick O, Bading H, Spatz JP, Fiammengo R: Conjugation of peptides to the passivation shell of gold nanoparticles for targeting of cell-surface receptors. ACS Nano. 4(11), 6617-6628 (2010).
51. Housni A, Ahmed M, Liu S, Narain R: Monodisperse protein stabilized gold nanoparticles via a simple photochemical process. J. Phys. Chem. C 112(32), 12282-12290 (2008).
52. Rosi NL, Mirkin CA: Nanostructures in biodiagnostics. Chem. Rev. 105, 1547-1562 (2005). (Pubitemid 40596871)
53. Luchini A, Geho DH, Bishop B et al.: Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano. Letters 8(1), 350-361 (2007). (Pubitemid 351177827)
54. Fredolini C, Meani F, Alex Reeder K et al.: Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles. Nano. Research 1(6), 502-518 (2008).
55. Longo C, Patanarut A, George T et al.: Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 4(3), e4763 (2009).
56. Cerasoli E, Rakowska PD, Horgan A et al.: MiS-MALDI: microgel-selected detection of protein biomarkers by MALDI-ToF mass spectrometry. Mol. Biosys. 6(11), 2214-2217 (2010).
57. Miller G: Alzheimer's biomarker initiative hits its stride. Science 326, 386-389 (2009).
58. Shankar GM, Li S, Mehta TH et al.: Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837-842 (2008).
59. Krafft GA, Klein WL: ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology 59(4-5), 230-242 (2010).
60. Grossman I, Lutz M, Crenshaw D, Saunders A, Burns D, Roses A: Alzheimer's disease: diagnostics, prognostics and the road to prevention. EPMA J. 1(2), 293-303 (2010).
61. Shaw LM, Korecka M, Clark CM, Lee VMY, Trojanowski JQ: Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6(4), 295-303 (2007). (Pubitemid 46505880)
62. Santos AN, Torkler S, Nowak D et al.: Detection of amyloid-b; oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J. Alzheimers Dis. 11(1), 117-125 (2007). (Pubitemid 46376713)
63. Nam JM, Jang KJ, Groves JT: Detection of proteins using a colorimetric bio-barcode assay. Nat. Protocols 2(6), 1438-1444 (2007). (Pubitemid 46952323)
64. Willets KA, Van Duyne RP: Localized surface plasmon resonance spectroscopy and sensing. Ann. Rev. Phys. Chem. 58(1), 267-297 (2007). (Pubitemid 46877591)
65. Georganopoulou DG, Chang L, Nam J-M et al.: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. USA 102(7), 2273-2276 (2005). (Pubitemid 40279365)
66. Keating CD: Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc. Natl Acad. Sci. USA 102(7), 2263-2264 (2005). (Pubitemid 40279360)
67. Solomon SB, Silverman SG: Imaging in interventional oncology. Radiology 257, 624-640 (2010).
68. Bathen TF, Sitter B, Sjøbakk TE, Tessem MB, Gribbestad IS: Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res. 70, 6692-6696 (2010).
69. Turkbey B, Pinto PA, Choyke PL: Imaging techniques for prostate cancer: implications for focal therapy. Nat. Rev. Urol. 6(4), 191-203 (2009).
70. Kumar S, Mohan A, Guleria R: Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 11(5), 385-405 (2006). (Pubitemid 44364079)
71. Zhao J, Patwa TH, Lubman DM, Simeone DM: Protein biomarkers in cancer: natural glycoprotein microarray approaches. Curr. Opin. Mol. Ther. 10(6), 602-610 (2008).
72. Le Page CC, Huntsman DG, Provencher DM, Mes-Masson AM: Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers 2(2), 913-954 (2010).
73. Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer - a survey. Biochim. Biophys. Acta 1775(1), 181-232 (2007). (Pubitemid 44911084)
74. Huang ZH, Li LH, Hua D: Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 243(1), 64-70 (2006). (Pubitemid 44485325)
75. Honeychurch J, Glennie MJ, Illidge TM: Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res. 65(16), 7493-7501 (2005). (Pubitemid 41161285)
76. Draghici S, Chatterjee M, Tainsky MA: Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev. Mol. Diagn. 5(5), 735-743 (2005). (Pubitemid 41337468)
77. Sreekumar A, Poisson LM, Rajendiran TM et al.: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009).
78. Couzin J: Metabolite in urine may point to high-risk prostate cancer. Science 323(5916), 865 (2009).
79. Martinkova J, Gadher SJ, Hajduch M, Kovarova H: Challenges in cancer research and multifaceted approaches for cancer biomarker quest. FEBS Lett. 583(11), 1772-1784 (2009).
80. Rowe MD, Thamm DH, Kraft SL, Boyes SG: Polymer-modified Gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromolecules 10(4), 983-993 (2009).
81. Renu J, Robabeh R, Steven GA et al.: In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes. Proc. Natl Acad. Sci.USA 107, 8085-8090 (2010).
82. Leber MF, Efferth T: Molecular principles of cancer invasion and metastasis. Int. J. Oncol. 34, 881-895 (2009).
83. Ruoslahti E: Specialization of tumour vasculature. Nat. Rev. Cancer 2, 83-90 (2002). (Pubitemid 37328795)
84. Bella A, Lewis H, Phu J et al.: Conformationally constrained mimetics of laminin peptide YIGSR as precursors for antimetastatic disintegrins. J. Med. Chem. 52(24), 7966-7969 (2009).
85. El-Sayed IH, Huang X, El-Sayed MA: Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett. 5(5), 829-834 (2005). (Pubitemid 40749040)
86. El-Sayed IH, Huang X, El-Sayed MA: Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239(1), 129-135 (2006). (Pubitemid 43946581)
87. Chanda N, Kattumuri V, Shukla R et al.: Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl Acad. Sci. USA 107(19), 8760-8765 (2010).
88. Ananias HJK, van den Heuvel MC, Helfrich W, de Jong IJ: Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69(10), 1101-1108 (2009).